|
EP3187182B1
(en)
|
2008-09-02 |
2021-03-03 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
|
KR20110091680A
(ko)
*
|
2008-10-17 |
2011-08-12 |
메타볼렉스, 인코포레이티드 |
작고 조밀한 ｌｄｌ 입자를 감소시키는 방법
|
|
BRPI1014405A2
(pt)
|
2009-04-29 |
2016-04-05 |
Amarin Corp Plc |
composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso
|
|
KR101343249B1
(ko)
|
2009-04-29 |
2013-12-19 |
아마린 파마, 인크. |
안정한 제약 조성물 및 그의 사용 방법
|
|
SMT201800261T1
(it)
|
2009-06-15 |
2018-07-17 |
Amarin Pharmaceuticals Ie Ltd |
Composizioni e metodi per abbassare i trigliceridi senza aumentare i livelli di ldl-c in un soggetto in concomitanza con la terapia con statine
|
|
RU2012116079A
(ru)
|
2009-09-23 |
2013-10-27 |
АМАРИН КОРПОРЕЙШН ПиЭлСи |
Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
|
|
WO2011140441A2
(en)
|
2010-05-06 |
2011-11-10 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
AU2011336856A1
(en)
|
2010-11-29 |
2013-07-04 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
US9827219B2
(en)
|
2012-01-06 |
2017-11-28 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
|
|
HUE072482T2
(hu)
|
2012-06-29 |
2025-11-28 |
Amarin Pharmaceuticals Ie Ltd |
Eikozapentaénsav-etilészter nem-halálos stroke sztatin terápiában résztvevõ betegeknél a nem-halálos stroke kockázatának csökkentésében történõ alkalmazásra
|
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
ES2701094T3
(es)
|
2014-03-20 |
2019-02-20 |
Cymabay Therapeutics Inc |
Tratamiento de enfermedades colestáticas intrahepáticas
|
|
KR102374499B1
(ko)
|
2014-04-11 |
2022-03-14 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
Nafld 및 nash 의 치료
|
|
US10174289B2
(en)
|
2014-05-28 |
2019-01-08 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
WO2016061464A1
(en)
|
2014-10-17 |
2016-04-21 |
Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center |
In vivo model of human small intetine using pluripotent stem cells and methods of making and using same
|
|
KR20170131644A
(ko)
*
|
2015-03-26 |
2017-11-29 |
티3디 테라퓨틱스, 인크. |
인단 아세트산 유도체를 사용한 간 질환의 치료 방법
|
|
BR112017023164A2
(en)
|
2015-04-28 |
2018-07-24 |
Pronova Biopharma Norge As |
and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
|
|
US10940125B2
(en)
|
2015-09-18 |
2021-03-09 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
WO2017139708A1
(en)
|
2016-02-10 |
2017-08-17 |
Synlogic, Inc. |
Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
US12053445B2
(en)
|
2016-03-31 |
2024-08-06 |
Genfit |
Methods of treatment of cholestatic diseases
|
|
US11066650B2
(en)
|
2016-05-05 |
2021-07-20 |
Children's Hospital Medical Center |
Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
|
|
GB201614455D0
(en)
|
2016-08-24 |
2016-10-05 |
Univ Oxford Innovation Ltd |
Biomarkers
|
|
KR102546194B1
(ko)
|
2016-11-04 |
2023-06-21 |
칠드런즈 호스피탈 메디칼 센터 |
간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
|
|
US10493363B2
(en)
*
|
2016-11-09 |
2019-12-03 |
Activision Publishing, Inc. |
Reality-based video game elements
|
|
JP7068305B2
(ja)
|
2016-12-05 |
2022-05-16 |
チルドレンズ ホスピタル メディカル センター |
結腸オルガノイドならびにその作製方法および使用方法
|
|
WO2018191673A1
(en)
|
2017-04-14 |
2018-10-18 |
Children's Hospital Medical Center |
Multi donor stem cell compositions and methods of making same
|
|
EP4234536A3
(en)
|
2017-05-05 |
2023-10-25 |
Hepanova, Inc. |
Amino-aryl-benzamide compounds and methods of use thereof
|
|
US10966951B2
(en)
|
2017-05-19 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US10512622B2
(en)
|
2017-07-14 |
2019-12-24 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
JP2020533339A
(ja)
|
2017-09-13 |
2020-11-19 |
ノバルティス アーゲー |
Ｆｘｒアゴニストを含む組合せ
|
|
CN111565798B
(zh)
|
2017-10-10 |
2025-06-24 |
儿童医院医学中心 |
食道组织和/或类器官组合物及其制备方法
|
|
EP3701953A4
(en)
*
|
2017-10-27 |
2021-06-16 |
Samyang Corporation |
COMPOSITION FOR THE PREVENTION OR RELIEF OF NON-ALCOHOLIC FAT LIVER DISEASE
|
|
IL275002B2
(en)
|
2017-12-06 |
2024-04-01 |
Basf As |
Fatty acid derivatives for treating non-alcoholic steatohepatitis
|
|
EP3727394A4
(en)
|
2017-12-21 |
2021-09-08 |
Children's Hospital Medical Center |
DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
WO2020023245A1
(en)
|
2018-07-26 |
2020-01-30 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
CA3112026A1
(en)
|
2018-09-12 |
2020-03-19 |
Children's Hospital Medical Center |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
RS65750B1
(sr)
|
2018-09-24 |
2024-08-30 |
Amarin Pharmaceuticals Ie Ltd |
Postupci smanjenja rizika od kardiovaskularnih događaja kod pacijenta
|
|
CA3118965A1
(en)
|
2018-11-16 |
2020-05-22 |
Cymabay Therapeutics, Inc. |
Treatment of obesity and its complications
|
|
EP3880185A1
(en)
*
|
2018-11-16 |
2021-09-22 |
CymaBay Therapeutics, Inc. |
Combination treatment of nafld and nash
|
|
CN121081472A
(zh)
|
2018-12-13 |
2025-12-09 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
JP7610533B2
(ja)
|
2019-05-31 |
2025-01-08 |
チルドレンズ ホスピタル メディカル センター |
造血幹細胞の生成および拡大方法
|
|
CA3154391A1
(en)
|
2019-09-12 |
2021-03-18 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
MX2022005467A
(es)
|
2019-11-12 |
2022-08-10 |
Amarin Pharmaceuticals Ie Ltd |
Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto con fibrilación auricular y/o aleteo auricular.
|
|
WO2021097034A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
|
|
WO2021097027A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of alcoholic liver disease
|
|
CN115811972A
(zh)
*
|
2020-05-13 |
2023-03-17 |
拓臻制药公司 |
肝脏病症的组合治疗
|
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|
|
WO2022238445A1
(en)
*
|
2021-05-11 |
2022-11-17 |
Genfit |
Ppar-agonists for use in the treatment of liver failure
|